{"id":29563,"date":"2024-05-06T07:30:29","date_gmt":"2024-05-06T02:00:29","guid":{"rendered":"https:\/\/fundsindia.com\/blog\/?p=29563"},"modified":"2024-05-06T09:06:43","modified_gmt":"2024-05-06T03:36:43","slug":"alpha-aurobindo-pharma-ltd-equity-research-desk","status":"publish","type":"post","link":"https:\/\/www.fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563","title":{"rendered":"Alpha | Aurobindo Pharma Ltd. &#8211; Equity Research Desk"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/aurobindo-pharma-ltd.png\"><img loading=\"lazy\" width=\"1024\" height=\"512\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/aurobindo-pharma-ltd-1024x512.png\" alt=\"\" class=\"wp-image-29576\" srcset=\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/aurobindo-pharma-ltd-1024x512.png 1024w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/aurobindo-pharma-ltd-300x150.png 300w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/aurobindo-pharma-ltd-768x384.png 768w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/aurobindo-pharma-ltd-1536x768.png 1536w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/aurobindo-pharma-ltd.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Aurobindo Pharma Ltd. \u2013 Committed to healthier life!<\/span><\/strong><\/h2>\n\n\n\n<p>Aurobindo Pharma Ltd., established in 1986 and headquartered in Hyderabad, is a global pharmaceutical company focusing on generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). With a diverse portfolio and a strong international presence, Aurobindo serves key therapeutic segments across 150 countries, backed by extensive R&amp;D capabilities.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Market-Data.png\"><img loading=\"lazy\" width=\"748\" height=\"500\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Market-Data.png\" alt=\"\" class=\"wp-image-29567\" srcset=\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Market-Data.png 748w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Market-Data-300x201.png 300w\" sizes=\"(max-width: 748px) 100vw, 748px\" \/><\/a><\/figure>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Product Portfolio of AUROPHARMA<\/span><\/strong><\/h2>\n\n\n\n<p>Aurobindo\u2019s service segments include formulations and APIs. Its diverse product portfolio consists of biosimilars, dermatology, respiratory, vaccines, peptides, oncology, hormones, and sterile products.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/SHP.png\"><img loading=\"lazy\" width=\"819\" height=\"302\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/SHP.png\" alt=\"\" class=\"wp-image-29569\" srcset=\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/SHP.png 819w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/SHP-300x111.png 300w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/SHP-768x283.png 768w\" sizes=\"(max-width: 819px) 100vw, 819px\" \/><\/a><\/figure>\n\n\n\n<p><strong>Subsidiaries:<\/strong> Aurobindo boasts 85 subsidiaries, 6 joint ventures, and 2 associate companies, enhancing its global footprint and diversification efforts.<\/p>\n\n\n\n<h2><span class=\"has-inline-color has-vivid-cyan-blue-color\">Growth Strategies of Aurobindo Pharma Ltd<\/span><\/h2>\n\n\n\n<ul><li>Diversification into injectables with a focus on EU and emerging markets.<\/li><li>Expansion into untapped global markets like China.<\/li><li>Clinical trial studies for biosimilar products.<\/li><li>Strong focus on the domestic formulation market.<\/li><li>Enhancing manufacturing capacity with specialized facilities:<ul><li>Commissioning a specialized injectable facility in Vizag to meet rising demand.<\/li><li>Installation of the Lyfius plant for Pen-G and the 6-APA plant.<\/li><\/ul><\/li><li>Aggressive product expansion in the US market:<ul><li>Filed 7 ANDAs and received approval for 16 products in Q3FY24.<\/li><li>Launched 21 products, including 4 specialty and injectable products.<\/li><\/ul><\/li><\/ul>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Financial Highlights of Aurobindo Pharma Ltd<\/span><\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Revenue-Breakup-FY23-_-Total-Revenue-FY23-Rs.-24855-crore-1.png\"><img loading=\"lazy\" width=\"633\" height=\"481\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Revenue-Breakup-FY23-_-Total-Revenue-FY23-Rs.-24855-crore-1.png\" alt=\"\" class=\"wp-image-29570\" srcset=\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Revenue-Breakup-FY23-_-Total-Revenue-FY23-Rs.-24855-crore-1.png 633w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Revenue-Breakup-FY23-_-Total-Revenue-FY23-Rs.-24855-crore-1-300x228.png 300w\" sizes=\"(max-width: 633px) 100vw, 633px\" \/><\/a><\/figure>\n\n\n\n<h2><span class=\"has-inline-color has-vivid-cyan-blue-color\">Q3FY24 Performance<\/span><\/h2>\n\n\n\n<ul><li>Revenue: Rs.7,352 crore (15% YoY increase).<\/li><li>Operating profit: 68% YoY growth to Rs.1,601 crore.<\/li><li>Net profit: Surged by 91% YoY to Rs.936 crore.<\/li><li>EBITDA margin: 22% (highest ever).<\/li><li>Gross margin: 57%.<\/li><\/ul>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Ratios.png\"><img loading=\"lazy\" width=\"749\" height=\"348\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Ratios.png\" alt=\"\" class=\"wp-image-29571\" srcset=\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Ratios.png 749w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Ratios-300x139.png 300w\" sizes=\"(max-width: 749px) 100vw, 749px\" \/><\/a><\/figure>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Financial Performance<\/span><\/strong><\/h2>\n\n\n\n<ul><li>Revenue and PAT growth: 15% and 30% respectively over the last twelve months.<\/li><li>ROE &amp; ROCE: Average of 14% and 16% respectively for FY18-23.<\/li><li>Debt-to-equity ratio: 0.24, indicating a robust capital structure.<\/li><\/ul>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Margin.png\"><img loading=\"lazy\" width=\"749\" height=\"208\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Margin.png\" alt=\"\" class=\"wp-image-29572\" srcset=\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Margin.png 749w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Margin-300x83.png 300w\" sizes=\"(max-width: 749px) 100vw, 749px\" \/><\/a><\/figure>\n\n\n\n<h2><span class=\"has-inline-color has-vivid-cyan-blue-color\">Industry Outlook<\/span><\/h2>\n\n\n\n<ul><li>Indian pharmaceutical industry poised to reach US$ 57 billion by FY25.<\/li><li>Projected CAGR of over 10% to reach US$ 130 billion by 2030.<\/li><li>Favorable regulatory environment with up to 100% FDI allowed for pharmaceutical projects.<\/li><li>Increasing focus on research and development, with government allocation for research and healthcare.<\/li><li>Growing emphasis on innovation and technology adoption to meet global healthcare demands.<\/li><\/ul>\n\n\n\n<h2><span class=\"has-inline-color has-vivid-cyan-blue-color\">Growth Drivers<\/span><\/h2>\n\n\n\n<ol><li>Government Allocation:<ul><li>Rs.3,201 crore (US$ 419.2 million) allocated for research.<\/li><li>Rs.83,000 crore (US$ 10.86 billion) allocated for the Ministry of Health and Family Welfare in Union Budget 2022-23.<\/li><\/ul><\/li><li>Global Demand for Generic Drugs:<ul><li>Indian pharmaceutical industry projected to grow at a CAGR of over 10% to reach US$ 130 billion by 2030.<\/li><li>India supplies over 40% of generic demand in the US.<\/li><\/ul><\/li><li>Cost Advantage and Efficient R&amp;D:<ul><li>India offers medicines at costs 30%-35% lower than the US and Europe.<\/li><li>R&amp;D costs in India are approximately 87% less than in developed markets.<\/li><\/ul><\/li><\/ol>\n\n\n\n<h2><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Competitive Advantage<\/span><\/strong><\/h2>\n\n\n\n<p>Compared to competitors like Lupin Ltd, Mankind Pharma Ltd, etc, Aurobindo Pharma Ltd has the following advantages<\/p>\n\n\n\n<ul><li>Undervalued stock with potential for P\/E expansion.<\/li><li>Strong margin and earnings growth compared to competitors like Lupin Ltd. and Mankind Pharma Ltd.<\/li><\/ul>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Peers.png\"><img loading=\"lazy\" width=\"1024\" height=\"146\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Peers-1024x146.png\" alt=\"\" class=\"wp-image-29573\" srcset=\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Peers-1024x146.png 1024w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Peers-300x43.png 300w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Peers-768x109.png 768w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Peers.png 1434w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2><span class=\"has-inline-color has-vivid-cyan-blue-color\">Outlook<\/span><\/h2>\n\n\n\n<ul><li>Aurobindo is poised for robust growth amidst US drug shortages.<\/li><li>Diverse product portfolio meets market needs.<\/li><li>Targeted FY24 EBITDA margin: 20%.<\/li><li>New facilities in China and Vizag enhance market presence.<\/li><li>Pipeline includes high-margin biosimilars and peptides.<\/li><li>Strategic initiatives ensure sustained success.<\/li><\/ul>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/image.png\"><img loading=\"lazy\" width=\"1024\" height=\"712\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/image-1024x712.png\" alt=\"\" class=\"wp-image-29574\" srcset=\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/image-1024x712.png 1024w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/image-300x209.png 300w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/image-768x534.png 768w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/image.png 1225w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2><span class=\"has-inline-color has-vivid-cyan-blue-color\">Valuation<\/span><\/h2>\n\n\n\n<ul><li>Aurobindo Pharma Ltd. is positioned for growth amidst heightened drug shortages, particularly in the US market.<\/li><li>With its expansion initiatives and optimization of product mix, Aurobindo Pharma Ltd. is poised to capitalize on market opportunities, warranting a BUY rating with a target price (TP) of Rs.1,361 by 28x FY25E EPS.<\/li><\/ul>\n\n\n\n<h2><span class=\"has-inline-color has-vivid-cyan-blue-color\">Risks<\/span><\/h2>\n\n\n\n<ul><li>Forex Risk: Exposure to forex fluctuations due to significant operations in foreign markets.<\/li><li>Regulatory Risk: Vulnerability to regulatory changes, especially scrutiny by agencies like USFDA, impacting operations.<\/li><\/ul>\n\n\n\n<p dir=\"ltr\" style=\"line-height: 1.8; margin-top: 0pt; margin-bottom: 0pt; text-align: center;\"><a href=\"https:\/\/fundsindia-marketing-assets.s3.ap-south-1.amazonaws.com\/Aurobindo+Pharma+Ltd+-+May+2024.docx.pdf\" target=\"_blank\" rel=\"noopener\"><img alt=\"\" src=\"https:\/\/fundsindia-marketing-assets.s3.ap-south-1.amazonaws.com\/button_read-the-full-alpha-report.png\" style=\"width: 320px; height: 49px;\" \/><\/a><\/p>\n\n\n\n<p><strong><span class=\"has-inline-color has-vivid-cyan-blue-color\">Recap of our previous recommendations (As on 03 May 2024)<\/span><\/strong><\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Recap.png\"><img loading=\"lazy\" width=\"926\" height=\"209\" src=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Recap.png\" alt=\"\" class=\"wp-image-29575\" srcset=\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Recap.png 926w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Recap-300x68.png 300w, https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/Recap-768x173.png 768w\" sizes=\"(max-width: 926px) 100vw, 926px\" \/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/www.fundsindia.com\/blog\/equities\/alpha-man-infraconstruction-ltd-equity-research-desk\/29536\">Man Infraconstruction Ltd<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.fundsindia.com\/blog\/equities\/alpha-petronet-lng-ltd-equity-research-desk\/29484\">Petronet LNG Ltd<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.fundsindia.com\/blog\/equities\/alpha-kpr-mill-ltd-equity-research-desk\/29457\">KPR Mill Ltd<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.fundsindia.com\/blog\/equities\/alpha-nmdc-ltd-equity-research-desk\/29391\">NMDC Ltd<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aurobindo Pharma Ltd. \u2013 Committed to healthier life! Aurobindo Pharma Ltd., established in 1986 and headquartered in Hyderabad, is a global pharmaceutical company focusing on generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). With a diverse portfolio and a strong international presence, Aurobindo serves key therapeutic segments across 150 countries, backed by extensive [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":29576,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[743,59],"tags":[744,541,746,1033,745,897,892,648,1046,522,870],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v17.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Stock Analysis on Aurobindo Pharma Limited - ALPHA<\/title>\n<meta name=\"description\" content=\"AUROPHARMA is the stock name of Aurobindo Pharma Ltd, a global pharmaceutical company, that develops, manufactures, and sells generic &amp; branded drugs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Stock Analysis on Aurobindo Pharma Limited - ALPHA\" \/>\n<meta property=\"og:description\" content=\"AUROPHARMA is the stock name of Aurobindo Pharma Ltd, a global pharmaceutical company, that develops, manufactures, and sells generic &amp; branded drugs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563\" \/>\n<meta property=\"og:site_name\" content=\"Insights\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/fundsindia\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-06T02:00:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-06T03:36:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/aurobindo-pharma-ltd.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Equities Desk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#organization\",\"name\":\"Wealth India Financial Services\",\"url\":\"https:\/\/www.fundsindia.com\/blog\/\",\"sameAs\":[\"https:\/\/www.facebook.com\/fundsindia\"],\"logo\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#logo\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2018\/07\/download.jpeg\",\"contentUrl\":\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2018\/07\/download.jpeg\",\"width\":189,\"height\":200,\"caption\":\"Wealth India Financial Services\"},\"image\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#logo\"}},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#website\",\"url\":\"https:\/\/www.fundsindia.com\/blog\/\",\"name\":\"Insights\",\"description\":\"Official blog of FundsIndia.com\",\"publisher\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fundsindia.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563#primaryimage\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/aurobindo-pharma-ltd.png\",\"contentUrl\":\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/aurobindo-pharma-ltd.png\",\"width\":2048,\"height\":1024},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563#webpage\",\"url\":\"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563\",\"name\":\"Stock Analysis on Aurobindo Pharma Limited - ALPHA\",\"isPartOf\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563#primaryimage\"},\"datePublished\":\"2024-05-06T02:00:29+00:00\",\"dateModified\":\"2024-05-06T03:36:43+00:00\",\"description\":\"AUROPHARMA is the stock name of Aurobindo Pharma Ltd, a global pharmaceutical company, that develops, manufactures, and sells generic & branded drugs.\",\"breadcrumb\":{\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fundsindia.com\/blog\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alpha | Aurobindo Pharma Ltd. &#8211; Equity Research Desk\"}]},{\"@type\":\"Article\",\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563#article\",\"isPartOf\":{\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563#webpage\"},\"author\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#\/schema\/person\/78222a5d6aef66b1f386dfa767382656\"},\"headline\":\"Alpha | Aurobindo Pharma Ltd. &#8211; Equity Research Desk\",\"datePublished\":\"2024-05-06T02:00:29+00:00\",\"dateModified\":\"2024-05-06T03:36:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563#webpage\"},\"wordCount\":591,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#organization\"},\"image\":{\"@id\":\"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/aurobindo-pharma-ltd.png\",\"keywords\":[\"Alpha\",\"Aurobindo Pharma Ltd\",\"Equity Research\",\"fundamental analysis\",\"FundsIndia Equity Research\",\"Growth Drivers\",\"Industry Analysis\",\"outlook\",\"pharma stock\",\"stock markets\",\"valuation\"],\"articleSection\":[\"Alpha\",\"Equity Research\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563#respond\"]}]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#\/schema\/person\/78222a5d6aef66b1f386dfa767382656\",\"name\":\"Equities Desk\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.fundsindia.com\/blog\/#personlogo\",\"inLanguage\":\"en-US\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2620d09063050fc426411ab6ea46fc72?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2620d09063050fc426411ab6ea46fc72?s=96&d=mm&r=g\",\"caption\":\"Equities Desk\"},\"sameAs\":[\"http:\/\/www.fundsindia.com\"],\"url\":\"https:\/\/www.fundsindia.com\/blog\/author\/equities-desk\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Stock Analysis on Aurobindo Pharma Limited - ALPHA","description":"AUROPHARMA is the stock name of Aurobindo Pharma Ltd, a global pharmaceutical company, that develops, manufactures, and sells generic & branded drugs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563","og_locale":"en_US","og_type":"article","og_title":"Stock Analysis on Aurobindo Pharma Limited - ALPHA","og_description":"AUROPHARMA is the stock name of Aurobindo Pharma Ltd, a global pharmaceutical company, that develops, manufactures, and sells generic & branded drugs.","og_url":"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563","og_site_name":"Insights","article_publisher":"https:\/\/www.facebook.com\/fundsindia","article_published_time":"2024-05-06T02:00:29+00:00","article_modified_time":"2024-05-06T03:36:43+00:00","og_image":[{"width":2048,"height":1024,"url":"https:\/\/fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/aurobindo-pharma-ltd.png","type":"image\/png"}],"twitter_misc":{"Written by":"Equities Desk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Organization","@id":"https:\/\/www.fundsindia.com\/blog\/#organization","name":"Wealth India Financial Services","url":"https:\/\/www.fundsindia.com\/blog\/","sameAs":["https:\/\/www.facebook.com\/fundsindia"],"logo":{"@type":"ImageObject","@id":"https:\/\/www.fundsindia.com\/blog\/#logo","inLanguage":"en-US","url":"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2018\/07\/download.jpeg","contentUrl":"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2018\/07\/download.jpeg","width":189,"height":200,"caption":"Wealth India Financial Services"},"image":{"@id":"https:\/\/www.fundsindia.com\/blog\/#logo"}},{"@type":"WebSite","@id":"https:\/\/www.fundsindia.com\/blog\/#website","url":"https:\/\/www.fundsindia.com\/blog\/","name":"Insights","description":"Official blog of FundsIndia.com","publisher":{"@id":"https:\/\/www.fundsindia.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fundsindia.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"ImageObject","@id":"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563#primaryimage","inLanguage":"en-US","url":"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/aurobindo-pharma-ltd.png","contentUrl":"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/aurobindo-pharma-ltd.png","width":2048,"height":1024},{"@type":"WebPage","@id":"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563#webpage","url":"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563","name":"Stock Analysis on Aurobindo Pharma Limited - ALPHA","isPartOf":{"@id":"https:\/\/www.fundsindia.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563#primaryimage"},"datePublished":"2024-05-06T02:00:29+00:00","dateModified":"2024-05-06T03:36:43+00:00","description":"AUROPHARMA is the stock name of Aurobindo Pharma Ltd, a global pharmaceutical company, that develops, manufactures, and sells generic & branded drugs.","breadcrumb":{"@id":"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fundsindia.com\/blog"},{"@type":"ListItem","position":2,"name":"Alpha | Aurobindo Pharma Ltd. &#8211; Equity Research Desk"}]},{"@type":"Article","@id":"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563#article","isPartOf":{"@id":"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563#webpage"},"author":{"@id":"https:\/\/www.fundsindia.com\/blog\/#\/schema\/person\/78222a5d6aef66b1f386dfa767382656"},"headline":"Alpha | Aurobindo Pharma Ltd. &#8211; Equity Research Desk","datePublished":"2024-05-06T02:00:29+00:00","dateModified":"2024-05-06T03:36:43+00:00","mainEntityOfPage":{"@id":"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563#webpage"},"wordCount":591,"commentCount":0,"publisher":{"@id":"https:\/\/www.fundsindia.com\/blog\/#organization"},"image":{"@id":"https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563#primaryimage"},"thumbnailUrl":"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/aurobindo-pharma-ltd.png","keywords":["Alpha","Aurobindo Pharma Ltd","Equity Research","fundamental analysis","FundsIndia Equity Research","Growth Drivers","Industry Analysis","outlook","pharma stock","stock markets","valuation"],"articleSection":["Alpha","Equity Research"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/fundsindia.com\/blog\/equities\/alpha-aurobindo-pharma-ltd-equity-research-desk\/29563#respond"]}]},{"@type":"Person","@id":"https:\/\/www.fundsindia.com\/blog\/#\/schema\/person\/78222a5d6aef66b1f386dfa767382656","name":"Equities Desk","image":{"@type":"ImageObject","@id":"https:\/\/www.fundsindia.com\/blog\/#personlogo","inLanguage":"en-US","url":"https:\/\/secure.gravatar.com\/avatar\/2620d09063050fc426411ab6ea46fc72?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2620d09063050fc426411ab6ea46fc72?s=96&d=mm&r=g","caption":"Equities Desk"},"sameAs":["http:\/\/www.fundsindia.com"],"url":"https:\/\/www.fundsindia.com\/blog\/author\/equities-desk"}]}},"jetpack_featured_media_url":"https:\/\/www.fundsindia.com\/blog\/wp-content\/uploads\/2024\/05\/aurobindo-pharma-ltd.png","_links":{"self":[{"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/posts\/29563"}],"collection":[{"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/comments?post=29563"}],"version-history":[{"count":5,"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/posts\/29563\/revisions"}],"predecessor-version":[{"id":29583,"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/posts\/29563\/revisions\/29583"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/media\/29576"}],"wp:attachment":[{"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/media?parent=29563"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/categories?post=29563"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fundsindia.com\/blog\/wp-json\/wp\/v2\/tags?post=29563"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}